カテゴリ： GlobalData, アメリカ, 企業調査

TRACON Pharmaceuticals Inc (TCON)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：TRACON Pharmaceuticals Inc (TCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8014
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：71
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. Its TRC102, is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In addition, it also offers products for the treatment of fibrosis, prostate cancer, and hematologic malignancies such as myeloma. TRACON conducts pre-clinical studies for various products. The company works in collaboration with universities and institutions. TRACON is headquartered in San Diego, California, the US.

TRACON Pharmaceuticals Inc (TCON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
TRACON Pharma Raises USD27 Million in Series B Venture Financing 13
Private Equity 15
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 15
Partnerships 16
Tracon Pharma Enters into Research Agreement with Tufts Medical Center 16
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 17
Licensing Agreements 19
Ambrx Enters into Licensing Agreement with TRACON Pharma 19
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 20
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 22
Equity Offering 23
TRACON Pharma to Raise up to USD11.5 Million in Public Offering of Shares 23
TRACON Pharma to Raise USD68 Million in Public Offering of Shares 24
Tracon Pharma Raises USD38.7 Million in Private Placement of Shares and Warrants 25
Tracon Pharma to Raise USD14.33 Million in Public Offering of Shares 27
TRACON Pharma Files Registration Statement for Public Offering of Shares 28
TRACON Pharma Raises USD1 Million in Private Placement of Shares 29
TRACON Pharma Raises USD17.4 Million in Public Offering of Shares 30
TRACON Pharma Raises USD36 Million in IPO 32
TRACON Pharma Raises USD5 Million in Private Placement of Shares 34
TRACON Pharmaceuticals Inc – Key Competitors 36
TRACON Pharmaceuticals Inc – Key Employees 37
TRACON Pharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Recent Developments 39
Financial Announcements 39
Aug 08, 2018: TRACON Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 39
May 09, 2018: TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 41
Feb 28, 2018: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 42
Nov 07, 2017: TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update 44
Aug 08, 2017: TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update 46
May 10, 2017: TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update 48
Feb 28, 2017: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 50
Research And Development 51
Apr 10, 2017: TRACON receives Most Innovative Clinical Trial Design award for Phase III angiosarcoma trial 51
Corporate Communications 52
May 30, 2018: TRACON Pharmaceuticals Appoints Mark Wiggins As Chief Business Officer 52
Apr 09, 2018: TRACON Pharmaceuticals Appoints Ted Wang As Board Director 53
Dec 04, 2017: TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board 54
Product News 55
11/09/2017: TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient in Patients with Soft Tissue Sarcoma Including Angiosarcoma 55
08/16/2017: TRACON Pharmaceuticals Announces Positive Results from National Cancer Institute Phase 1/2 Trial of TRC105 and Nexavar in Hepatocellular Cancer Published in Clinical Cancer Research 56
02/12/2018: Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients with Refractory Wet Age-Related Macular Degeneration 57
01/19/2018: TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients 58
Clinical Trials 59
Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer 59
Nov 29, 2017: TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung Cancer 60
Oct 15, 2017: TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer 61
Sep 07, 2017: TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta in Renal Cell Carcinoma 62
Jul 25, 2017: Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration 63
Jun 05, 2017: TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 Study at American Society of Clinical Oncology 2017 Annual Meeting 64
May 25, 2017: TRACON To Present Clinical Data for Carotuximab at Upcoming ASCO Annual Meeting 65
May 11, 2017: TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia 66
Apr 10, 2017: TRACON Awarded ‘Most Innovative Trial Design’ for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards 67
Feb 16, 2017: TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma 68
Feb 09, 2017: TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma 69
Jan 03, 2017: TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement from FDA for Phase 3 Clinical Trial of TRC105 in Angiosarcoma 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TRACON Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
TRACON Pharma Raises USD27 Million in Series B Venture Financing 13
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 15
Tracon Pharma Enters into Research Agreement with Tufts Medical Center 16
Tracon Pharma Enters Into Co-Development Agreement With Santen Pharma 17
Ambrx Enters into Licensing Agreement with TRACON Pharma 19
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 20
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 22
TRACON Pharma to Raise up to USD11.5 Million in Public Offering of Shares 23
TRACON Pharma to Raise USD68 Million in Public Offering of Shares 24
Tracon Pharma Raises USD38.7 Million in Private Placement of Shares and Warrants 25
Tracon Pharma to Raise USD14.33 Million in Public Offering of Shares 27
TRACON Pharma Files Registration Statement for Public Offering of Shares 28
TRACON Pharma Raises USD1 Million in Private Placement of Shares 29
TRACON Pharma Raises USD17.4 Million in Public Offering of Shares 30
TRACON Pharma Raises USD36 Million in IPO 32
TRACON Pharma Raises USD5 Million in Private Placement of Shares 34
TRACON Pharmaceuticals Inc, Key Competitors 36
TRACON Pharmaceuticals Inc, Key Employees 37

List of Figures
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TRACON Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TRACON Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[TRACON Pharmaceuticals Inc (TCON)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Foamix Pharmaceuticals Ltd (FOMX)：企業の財務・戦略的SWOT分析
    Summary Foamix Pharmaceuticals Ltd (Foamix), formerly Foamix Ltd is a pharmaceutical company that develops and commercializes proprietary topical drugs for various dermatological therapies. The company’s product candidates include FMX101, a minocycline foam which is intended for the treatment of mod …
  • Topdanmark AS (TOP)：企業の財務・戦略的SWOT分析
    Topdanmark AS (TOP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • B&N Bank (Joint-Stock Company)：企業の戦略・SWOT・財務情報
    B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report Summary B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Flight Centre Travel Group Limited (FLT)：企業の財務・戦略的SWOT分析
    Flight Centre Travel Group Limited (FLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Marston’s PLC：企業の戦略・SWOT・財務情報
    Marston's PLC - Strategy, SWOT and Corporate Finance Report Summary Marston's PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • GoldStone Resources Ltd (GRL)：企業の財務・戦略的SWOT分析
    Summary GoldStone Resources Ltd (GoldStone) is a mining and mineral exploration company. The company acquires, explores, develops and produces gold properties. It offers exploration projects such as Homase-Akrokeri permits, Manso Amenfi permits, Sangola permits, Oyem permits and Ngoutou permits, amo …
  • Discovery Communications, Inc.：企業の戦略・SWOT・財務分析
    Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Dubai Electricity and Water Authority：電力：M&Aディール及び事業提携情報
    Summary Dubai Electricity and Water Authority (DEWA) is an electricity and water utility. It generates, transmits and distributes electricity; and desalinates water. The authority produces electricity using gas and steam turbines, and solar PV plants. DEWA’s plants include Jebel Ali Station D, E and …
  • Samyang Biopharmaceuticals Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Samyang Biopharmaceuticals Corp (Samyang Biopharm) researches and develops technology platforms for drug delivery. Its product portfolio comprises transdermal patches, injections, ORC hemostat and others. The company spans its expertise in the development and distribution of biodegradable, s …
  • Nippon Light Metal Holdings Co Ltd：企業の戦略・SWOT・財務情報
    Nippon Light Metal Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Light Metal Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Herantis Pharma Plc (HRTIS)：医療機器：M&Aディール及び事業提携情報
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • Extreme Networks, Inc. (EXTR)：企業の財務・戦略的SWOT分析
    Extreme Networks, Inc. (EXTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Koch Enterprises, Inc.：企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Olympic Mountain and Marine Products, Inc.：企業の戦略・SWOT・財務情報
    Olympic Mountain and Marine Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Olympic Mountain and Marine Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Aegean Marine Petroleum Network Inc (ANW)：企業の財務・戦略的SWOT分析
    Aegean Marine Petroleum Network Inc (ANW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Orange and Rockland Utilities, Inc.：企業の戦略的SWOT分析
    Orange and Rockland Utilities, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • The PNC Financial Services Group Inc：企業のM&A・事業提携・投資動向
    The PNC Financial Services Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The PNC Financial Services Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Danville Materials Inc：医療機器：M&Aディール及び事業提携情報
    Summary Danville Materials Inc (Danville), a subsidiary of Inverness Graham Investments is a medical device company that manufactures dental equipment. The company provides posts, air abrasion, tin plating, adhesives, sand blasting, composites, air polishing, dust cabinets, microetcher, and IPR. It …
  • HCL Infosystems Limited：企業の戦略・SWOT・財務分析
    HCL Infosystems Limited - Strategy, SWOT and Corporate Finance Report Summary HCL Infosystems Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Birchcliff Energy Ltd (BIR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Birchcliff Energy Ltd. (Birchcliff) is an intermediate oil and gas company that explores for, develops and produces natural gas, light oil and natural gas liquids. Its product portfolio includes crude oil, natural gas, natural gas liquids, and light and medium oils. The company operates in t …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆